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Building a Better Vector: The Manipulation of AAV Virions
Joseph E. Rabinowitz1 and R. Jude Samulski
The Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599Received September 25, 2000; accepted October 16, 2000; published online November 22, 2000This review will focus on research directed at manip-
ulating the virion of adeno-associated virus (AAV) with
the goals of circumventing the immune response of the
virion, as well as retargeting the virus to specific cell
types of interest. The use of five AAV serotypes for
addressing questions of Ab neutralization, novel tropism,
as well as providing natural templates for targeting by
virion modification will be discussed.
AAV BIOLOGY
Adeno-associated virus type 2 (AAV2) is a small (20–25
nm), single-stranded DNA (4680 nucleotide), nonenvel-
oped, parvovirus that has emerged as a major player in
the viral gene delivery arena. The only cis components
equired to generate AAV2 vectors are the two 145-
ucleotide inverted terminal repeats [for review, see
Samulski et al., 1999)]. These terminal repeats are re-
uired for the replication and packaging of the recombi-
ant genome into the newly formed AAV virions
McLaughlin et al., 1988; Samulski et al., 1989). The virion
s composed of three structural proteins, Vp1, Vp2, and
p3, that form the 60-subunit viral particle in a ratio of
:1:20, respectively. The structural proteins are trans-
ated from three overlapping transcripts of a single struc-
ural gene that differ due to alternative splicing and start
odon usage. Therefore, alterations made in the Vp3
oding domain will be present in all 60 subunits while
lterations in Vp1 will be present in approximately 3
ubunits.
Properties of the wildtype (wt)AAV type 2 as well as
dvances in the production of rAAV type 2, including the
limination of helper virus contamination (Ferrari et al.,
1997) and purification by column chromatography (Zolo-
tukhin et al., 1999) have helped advanced recombinant
1 To whom correspondence and reprint requests should be ad-
ressed at Gene Therapy Center, University of North Carolina at Chapel
ill, 7119 Thurston-Bowles CB# 7352, Chapel Hill, NC 27599-7352. Fax:
(919) 966-0907. E-mail: rjs@med.unc.edu
301(r)AAV type 2 use in gene therapy applications. Like
nonpathogenic wtAAV type 2, rAAV infects both dividing
and nondividing cells and establishes latency for the life
of the cell. Although the natural route of infection for
wtAAV is upper respiratory, rAAV has demonstrated in-
fection and long-term expression of transgenes in the
brain, liver, muscle, retina, and vasculature of experimen-
tal animals (Samulski et al., 1999).
Ironically, the broad tissue tropism once considered
an advantage of AAV type 2 might be viewed as a liability.
The ideal clinical situation for a viral vector would be the
delivery of a gene therapy agent by the least invasive
manner in the lowest dose required. This could be ac-
complished if the delivery agent were able to specifically
target the organ or tissue most affected by the condition,
thereby lowering the effective dose required. The appeal
of targeting vectors is the potential for a simple injection
of the transfer vehicle to exclusively localize to and
transduce the target tissue. For this ideal to become a
reality, a number of steps must be accomplished. The
foremost obstacle is the host immune response against
the virus.
IMMUNE RESPONSE AGAINST AAV
Two aspects of the immune response against AAV
type 2-based vectors in gene therapy applications, pre-
existing immunity and the potential need for readminis-
tration, have generated the interest for research using
other serotypes and manipulating the virion to alter an-
tigenic determinants.
One of the challenges facing the successful use of
AAV type 2 as a gene therapy tool is the impact of natural
immunity to the virion. To understand the scope of this
challenge, studies have determined the prevalence of
serum antibodies in the population. These studies have
defined the subset of the population with seropositive
antibodies against AAV type 2 between 50 and 96%, with
18 to 67.5% being neutralizing (Blacklow et al., 1968;
Chirmule et al., 1999; Erles et al., 1999; Moskalenko et al.,
0042-6822/00 $35.00
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302 MINIREVIEW2000). In experimental animals, neutralizing antibodies
have been shown to eliminate (Fisher et al., 1997; Kessler
et al., 1996; Xiao et al., 1996) or greatly reduce (Chirmule
t al., 2000; Xiao et al., 2000) the levels of transgene
xpression of the readministered vector. Two studies
eport conflicting results upon readministration to the
abbit lung in the presence of neutralizing antibodies.
ne study demonstrates transgene expression after the
hird administration, while the other shows no expres-
ion upon readministration (Halbert et al., 1997; Hernan-
ez et al., 1999). Some of these discrepancies may be
elated to the purity of the vector and method for admin-
stration. However, with the exception of lung, most stud-
es have determined the block to readministration to be
humoral response associated with T-cell-dependent B
ell activation against the virion and not the transgene
roduct as seen with other viral vectors (Chirmule et al.,
000; Hernandez et al., 1999). These results are sup-
orted by studies of transient immunosuppression dur-
ng primary administration which allows successful re-
dministration of the same vector (Halbert et al., 1998;
anning et al., 1998). Although these observations sup-
ort humoral response to the AAV virion as the major
mmune response in rAAV animal studies, two excep-
ions are noted. A cell-mediated immune response to
ransgenes expressing a foreign cell surface viral glyco-
rotein, and a foreign secreted protein were observed
fter rAAV infection (Brockstedt et al., 1999; Manning et
l., 1998). A cell-mediated immune response to the trans-
ene expressed from AAV is rare, and one explanation
ay relate to inefficient transduction of mature dendritic
ells and the presentation of neoantigen (Jooss et al.,
998; Zhang et al., 2000). The virus unsuccessful infec-
T
Pairwise Comparison of Amin
Serotypea Total (%)b Vp1 (%) Vp
1vs2 122 (16.6) 21 (15.3) 13 (2
1vs3 102 (13.9) 11 (8.0) 13 (2
1vs4 289 (39.4) 16 (11.8) 34 (5
1vs5 323 (44.6) 39 (28.7) 55 (9
2vs3 94 (12.8) 20 (14.6) 14 (2
2vs4 296 (40.3) 28 (20.6) 38 (6
2vs5 316 (43.6) 44 (32.3) 50 (8
3vs4 290 (39.5) 14 (10.3) 41 (6
3vs5 310 (42.8) 35 (25.7) 53 (9
4vs5 385 (53.2) 40 (29.4) 65 (1
a Pairwise alignments were based on AAV5 capsid alignment (Chior
b Total number and percentage differences of amino acids including
c Variable domain extends from tyrosine 443 to lysine 601 (AAV2 nu
differences in Vp3 between paired serotypes.
d Percentage of different amino acids in variable domain between pion of mature dendritic cells may allow for the intracel-
ular expression in target cells and immunologic toler-
w
snce of foreign antigens. These studies not only illustrate
he need to better understand the immune response
gainst AAV type 2 but also a need to develop new
trategies to overcome or circumvent neutralizing anti-
odies existing in the population. Two obvious ap-
roaches are available: one strategy would utilize the
ther AAV serotypes as alternative vectors, the second
trategy would alter domains of AAV type 2 that are
mmunogenic so that preexisting neutralizing antibodies
ill not hinder readministration.
SEROTYPES
The five serotypes of AAV represent a group of repli-
ation defective viruses that are a rare resource for the
ene therapy community. Questions related to their po-
ential utility are (1) How similar are they to the type 2
ector? (2) Will neutralizing antibodies cross-react with
hese virions? And (3) Do the serotypes have biologically
elevant differences such as tissue tropism?
All of the AAV serotypes have been sequenced and
ive of the six have significantly divergent amino acid
equences. Serotypes 1 and 6 share .99% amino acid
omology in their capsid proteins, and sequence analy-
is supports a recombination event between types 1 and
resulting in isolation of this laboratory strain type 6
Rutledge et al., 1998; Xiao et al., 1999). For simplicity, we
ill refer to AAV type 1 in this review. The degree of
ifference between the five serotypes is shown in Table
. Pair-wise comparisons of amino acid sequences be-
ween each serotype were made. The total number and
ercentage difference between each serotype for the
ntire capsid, Vp1, Vp2, and Vp3 and the variable domain
Sequences in AAV Serotypes
Vp3 (%)
Variable
(% of Vp3)c
% difference
in variabled
88 (16.5) 66 (75) 41.50
78 (14.6) 49 (63) 30.80
239 (44.8) 128 (54) 80.50
229 (43.0) 123 (54) 77.40
60 (11.3) 47 (78) 29.60
230 (43.2) 119 (52) 74.80
222 (41.7) 119 (54) 74.80
235 (44.1) 125 (53) 78.60
222 (41.7) 116 (52) 73.00
280 (52.6) 143 (51) 89.90
l., 1999).
ions and deletions.
. Total number and percentage of differences in variable domain over
erotypes.ABLE 1
o Acid
2 (%)
0.0)
0.0)
6.7)
8.2)
1.5)
3.3)
9.3)
8.3)
4.6)
16.1)b
ini et a
insert
mbers)ithin Vp3 are reported (Table 1). From these compari-
ons, three groups of serotypes emerge based on their
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303MINIREVIEWtotal percentage difference. Original evidence suggests
that AAV types 1, 2, and 3 were serologically distinct
based on complement fixation assays derived from
guinea pig sera, an assay that requires 109 particles for
detection (Hoggan et al., 1966; Parks, 1967). Sera epide-
iological studies of AAV types 1, 2, and 3 in pediatric
atients demonstrated near identical neutralizing anti-
ody profiles suggesting simultaneous infection by all
hree viruses (Blacklow et al., 1968). However contrary to
hese observations, AAV type 1 has never been seen in
linical isolates (Blacklow et al., 1971). Amino acid se-
uence identity as shown in Table 1 demonstrates that
AV types 1, 2, and 3 may be more similar antigenetically.
herefore, defining of the AAV serotypes by complement
ixation assays may not reflect their role in nature. We
ave used a compilation of sequence data, serological
nd biological features to help define the 5 serotypes of
AV.
The first group consisting of AAV types 1, 2, and 3
hare homology across the three capsids with 8 to 21.5%
ifferences in Vp1, Vp2, and Vp3. The most divergent
egion of the capsid is located in Vp3 and referred to as
he variable domain (see Table 1). Interestingly, members
f this group all bind heparan sulfate (Summerford and
amulski, 1998); unpublished data) and antibodies can
ross-react to varying degrees (Blacklow et al., 1968;
lacklow, 1971). AAV types 4 and 5 do not share homol-
gy across the three capsids. Compared to types 1, 2,
nd 3, with the exception of the AAV4 Vp1 domain, these
iruses appear distinct (see Table 1). The uncommon
imilarity of the Vp1 domain shared between AAV sero-
ypes 1, 2, 3, and 4 is suggestive of a recombination
vent. The amino acid sequences of Vp 2 and 3 of
erotypes 4 and 5 are as different from each other as
rom those in group 1. This attribute is most likely why
erotype 4 and 5 are also immunologically distinct. There
s no serological evidence that AAV types 4 and 5 have
ross-neutralizing antibodies, and neither of these vi-
uses are competed by soluble heparan sulfate (Chiorini
t al., 1999) suggesting that they may use distinct and
nique receptors. Comparing the degree of capsid ho-
ology between the AAV serotypes and some autono-
ous parvoviruses reveals just how potentially different
he AAV serotypes can be.
Some autonomous parvoviruses contain minor
hanges in the capsid amino acids that result in differ-
nces in host ranges and tissue tropism. To illustrate this
oint, less than a dozen amino acid differences exist
etween feline panleukopenia and canine parvoviruses
apsids (Chang et al., 1992). Furthermore, only two
mino acid substitutions are required to change the
mmunosuppressive T cell tropism of MVM (MVMi) to a
onlethal fibrotropic strain (MVMp) (Ball-Goodrich and
attersall, 1992). By comparing these relatively subtle
hanges which result in alterations in host range and
issue tropism to the degree of capsid homology be-ween AAV serotypes one might conclude that the AAV
erotypes would have nothing in common. However, it
hould be noted that these divergent amino acids of the
utonomous parvoviruses are all surface localized
ased on crystal structure analysis, an interpretation not
vailable for the serotypes of AAV. Therefore, experimen-
al analysis has been used to establish that the differ-
nces in the amino acid sequences between AAV sero-
ypes are biologically significant. As mentioned above,
vidence regarding cross-neutralizing antibodies be-
ween the different serotypes in animals and human was
ne of the first points established when studying AAV
Hoggan et al., 1966).
New studies analyzing neutralization antibodies in an-
imals has demonstrated that the route of infection is
important, with AAV type 2 neutralizing AAV type 1 when
both are administered through the spleen, but not if
administered through the muscle (Xiao et al., 1999). This
may help explain the early results observed by Blacklow
and colleagues in humans suggesting that two out of
three AAV positive adults had neutralizing antibodies
against AAV types 1, 2, and 3 although type 1 has never
been isolated from clinical specimens (Blacklow et al.,
1971). Therefore, it is important to note that readminis-
tration of vector using AAV serotypes 1 versus 2 will
depend on the route of administration. This is not the
case for serotypes 4 and 5. Neutralizing antibodies
against serotypes 4 or 5 developed in mice do not cross-
react with any other serotype (Li and Samulski, unpub-
lished data). Another recent study identifying the immu-
nogenic epitopes of AAV type 2 capsid using overlapping
peptides that block neutralizing antibody binding has
been attempted (Moskalenko et al., 2000). Mapping
these peptides onto an alignment of the different sero-
types reveals several regions that are conserved. Infor-
mation obtained from this type of analysis could lead to
the genetic alteration of those amino acids in an effort to
alter the immune response. Alternatively, using these
peptides as Ab blocking reagents may allow for repeated
administration. Regardless of the approach, all of these
data support further analysis of AAV vectors and host cell
immune response when using different AAV serotypes.
SEROTYPE TROPISM
In addition to the different immune responses seen
using AAV serotypes, different biological aspects such
as tissue tropism have been observed. Xiao and co-
workers have compared AAV type 1 and AAV type 2 in
both liver and muscle (Xiao et al., 1999). Using equivalent
numbers of viral genomes, the levels of transduction in
liver were 10- to 50-fold greater for AAV type 2 vectors. In
contrast, AAV type 1 vectors produced ;100% more
transgene product in muscle (Xiao et al., 1999). This may
imply differences in viral entry, trafficking, uncoating, or
other unidentified steps when infecting specific cell
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304 MINIREVIEWtypes (Bartlett, 2000; Summerford and Samulski, 1998;
Chiorini, 1999). In another report comparing AAV sero-
types 2, 4, and 5 in vivo, investigators observed different
regional distribution and transduction efficiency in the
central nervous system at three and fifteen weeks after
injection (Davidson et al., 2000). The regional transduc-
ion in either striatal cells or intraventricularly may par-
ially reflect primary receptor binding differences, how-
ver efficiencies are still questionable since the titers
sed were not equal. Regardless, these results suggest
hat the differences in capsid amino acids can impact
oth immune and transduction profiles. For example,
nalysis of AAV type 2 and 5 for binding and transduction
f human airway epithilia cells and in mouse lungs also
emonstrated tropism differences. AAV type 5 bound (5-
o 10-fold better) and transduced (50-fold) more efficiently
han type 2 (Zabner et al., 2000). Although these differ-
nces are intriguing and highlight the advantage of hav-
ng multiple replication defective AAV serotypes to test, it
lso points to an area of concern when comparing se-
otype specific vectors, namely determining titer. In all of
he above studies, particle numbers were generally used
o determine titer. It is apparent that in addition to im-
une and tropism differences observed for the AAV
erotypes, physical to infectious particle numbers may
lso vary. These differences would greatly influence in-
erpretation of in vivo transduction data (Davidson et al.,
000; Xiao et al., 1999; Zabner et al., 2000). The infectious
enter assay was developed specifically to determine
he number of infectious particles within a stock (Haber-
an et al., 1999). It is apparent that utilization of this
ssay will be required when comparing transduction
fficiencies between different AAV serotype vectors.
The differences in the tropisms of the serotypes have
ust begun to be studied in animal models. Large-scale
iodistribution studies should elucidate tissue tropism
ifferences between the serotypes and help match the
ppropriate vector with target tissues. For these studies
o be of clinical use, it is important that serotype-specific
ropism established in animals translates to humans.
egardless, the elucidation of the mechanism of tissue
ropism observed for the different AAV serotypes will
elp in designing AAV-specific targeting vectors.
MODIFICATIONS OF AAV TYPE 2 VIRION FOR
GENE THERAPY APPLICATIONS
Why modify the virion? The appeal of targeting a vector
o a specific cell type has generated the interest in
odifying the virion of AAV type 2. Two approaches have
een used to modify AAV’s virion: chemically cross-
inked bifunctional antibodies and genetic manipulation
f the capsid gene. Chemical cross-linking is an ap-
roach that does not require knowledge of the crystal
tructure or surface-displayed domains (Fig. 1A). How-
ver, the genetic approach relies on identification ofositions on the virion surface (Fig. 1B) in order to modify
he capsid in an efficient manner. Eliminating primary
eceptor binding as a way of restricting the natural host
ange, while adding surface-localized targeting moieties
o broaden or specify the virus tropism, is the ultimate
oal of both approaches. Early developments in AAV type
vector retargeting will be described.
The use of chemically cross-linked monoclonal anti-
odies to target AAV type 2 to a nonpermissive cell line
as recently been demonstrated. A bispecific F(ab9g)2
antibody was constructed (Fig. 1A) with specificity for the
virion of AAV type 2 and the surface receptor a IIbb3
integrin (Bartlett et al., 1999). After incubation of virus
with bispecific antibody, modified virions were able to
transduce the nonpermissive human megakaryoblast
cells, demonstrating an extension of AAV type 2 host
range (Bartlett et al., 1999). While showing the feasibility
of this approach, the modified virions also displayed a
slight reduction in transduction efficiency in permissive
HeLa cells (Bartlett et al., 1999). In these experiments, a
monoclonal antibody that neutralizes AAV type 2 was
used for the virion binding ligand (Wistuba et al., 1995).
The use of a high-avidity neutralizing monoclonal anti-
body as one component of the bispecific Ab may have
decreased the infectivity of this virus to nontargeted cell
lines. The potential for this strategy is only limited by the
chemistry involved in constructing the reagents, the de-
termination of cell-type-specific receptors that mediate
endocytosis, and the efficiency of generating optimum
cross-linked virions.
A second approach for altering AAV type 2 tropism is
to genetically alter the capsid coding region. For this to
be successful, the location of domains on the surface of
the virion must be determined. The crystal structure of
autonomous parvoviruses has determined surface
amino acids and topology accessible for epitope manip-
ulation. In the absence of a crystal structure, three strat-
egies have been employed to determine those amino
acids or domains with surface orientation for AAV type 2.
In one innovative approach, a collection of overlapping
AAV type 2 capsid peptides was generated. These pep-
tides were incubated with AAV type 2 neutralizing serum
to determine if any would block binding activity, thereby
defining peptides pools that represent immunogenic re-
gions on the surface of the virion (Moskalenko et al.,
000). These regions are now available for genetic ma-
ipulation by linker oligo insertion analysis. In two other
tudies, aligning the capsid amino acid sequence of AAV
ype 2 with the known crystal structure of CPV has
llowed inferences about surface localization. Both in-
estigative groups predicted similar regions of the cap-
id that would be surface localized (Girod et al., 1999;
Wu, 2000). Mutational analysis in these sites has estab-
lished defined positions on the surface of the virion. The
final approach utilized classical random linker insertion
mutagenesis (Rabinowitz et al., 1999). All of these studies
he epit
305MINIREVIEWwere accomplished by inserting foreign epitopes either
randomly (Rabinowitz et al., 1999; Wu, 2000), at positions
predicted to be displayed (Girod et al., 1999; Wu, 2000),
or at the amino and carboxy termini (Wu, 2000; Yang et
al., 1998).
A major goal in developing a targeted vector is to
reduce the level of transduction of nontarget cells. From
the random mutagenesis approach, a 4-amino-acid in-
sertion at position 520 resulted in an AAV virion that lost
FIG. 1. Methods to manipulate the virion of AAV. (A) The antigen bi
cross-linking resulting in a F(ab)92 with two different antigen binding m
(yellow) binds a cell surface receptor that mediates a new tropism. G
epitope that mediates binding to a specific receptor. In this illustration t
on the surface of the virion (red).the ability to bind heparin affinity columns and infect
HeLa cells while still protecting the vector DNA (Rabi-nowitz et al., 1999). Additional mutational studies using
the CPV alignment approach revealed two clusters of
amino acids (509–522 and between 561 and 591) that
also reduced or eliminated heparin column binding and
in vitro transduction (Wu, 2000). These observations be-
gin to define the region of AAV type 2 required for recep-
tor binding. In contrast to the capsid domains identified
above, an infectious AAV type 2 mutant containing a
14-amino-acid insertion at position 587 was still inhibited
ragments (Fab) of two monoclonal antibodies are joined by chemical
. Here one Fab (green) binds the virion surface (red) and the other Fab
odification of the capsid (B) introducing the coding sequence for an
ope (yellow) is present at the fivefold axis of symmetry of each subunitnding f
oieties
enetic mby soluble heparin (Girod et al., 1999). The viable mutant
at position 587 and the fact that the cluster domain
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306 MINIREVIEWmutants do not contain a classical heparin binding motif
suggest that loss of heparin binding to these mutants is
due to conformational changes. Regardless, these mu-
tant virions represent a starting point for developing a
targeting virus without normal host range.
Once the normal tropism is eliminated, retargeting the
virion becomes the next challenge. As described above,
insertional mutagenesis strategies identifying positions
within the capsid that can tolerate exogenous amino
acids have been determined (Fig. 1B) (Girod et al., 1999;
abinowitz et al., 1999; Wu, 2000). Surface localization
as established by engineering targeting ligands into
hese positions (Table 2) (Girod, 1999; Wu, 2000; Rabi-
owitz, unpublished data). One insertion mutant at amino
cid position 34, containing a serpin epitope, was shown
o be infectious and mediate host range extension (Wu,
000). Using CPV for alignment, 12 predicted positions
ere examined for surface localization of which 9 were
ositive. Of the 9 positives, 5 were infectious but with
T
Compilation of Epitope
Amino acid
positiona Titerb A20 (6)c Surface
261 1 3 1012 Negative ND
266 1 3 107 Positive Positiv
328 1 3 107 Positive Positiv
381 1 3 1012 Negative Unkno
447 1 3 109 Positive Positiv
447 1 3 1013 Positive Positiv
522 1 3 109 Positive Positiv
534 5 3 1011 Positive Negati
553 1 3 109 Positive Positiv
573 1 3 1012 Positive Positiv
587 4 3 1013 Positive Positiv
591 1 3 109 Positive Positiv
664 1 3 109 Positive Positiv
1 1 3 109 Positive Positiv
138 1 3 1010 Positive Positiv
138 ND ND Positiv
203 Undetectable Negative No cap
735 Undetectable Negative No cap
28 2.5 3 1011 Positive Negati
34 1 3 1010 Positive Positiv
517 2.4 3 1010 Positive Positiv
529 1.5 3 1011 Positive Positiv
586 5 3 1011 Positive Positiv
a The first 12 positions were determined by alignment with CPV. The
etermined by insertional mutagenesis.
b Physical titers/ml were determined by dot-blot hybridization or A20
c A20 is a mouse monoclonal antibody that recognizes an AAV2 con
d Determined by ELISA or immunoprecipitation.
e Infectious titers are defined for virions with epitope inserts on AAV
f Extended host range on nonpermissive cell types (listed) for AAV2
g RGD epitope (QAGTFALRGDNPQG), HA (YPYDVPDYA), SERP (serp
inin AGSGGGSRPPGFSPRSGGA).iters at least two logs lower than wild type (Girod et al.,
999; Wu, 2000) (Table 2). Of the 5 infectious mutants,nly 1 with a 14-amino-acid RGD insertion at amino acid
87 extended the host range of rAAV type 2 (Girod et al.,
999). These results point to the need for the AAV type 2
rystal structure.
In another set of studies, targeting epitopes were
nserted at the amino termini of Vp1, Vp2, and Vp3 as well
s the carboxy termini of Vp3 (Wu, 2000; Yang et al.,
998). As described above, insertions at the amino ter-
inus of Vp2 were shown to mediate host range exten-
ion in the case of the serpin epitope (Wu, 2000). The use
f a CD34 specific single-chain antibody fusion to Vp2
ells yielded mixed results. The mutant capsid was un-
ble to generate transducing complexes unless wild-
ype helper plasmid was present which yielded titers of
3 102. Since viable virions were never characterized by
EM or Western and evidence exists for AAV pseudo
transduction (Alexander et al., 1997), the exact mecha-
nism of this targeting remains unresolved.
These studies demonstrate the difficult task of deter-
ions into AAV2 Capsid
Infectiouse Extend host range f Epitopeg
ND ND RGD
6 3 107 ND HA
No No HA
ND ND RGD
6 3 107 No HA
1 3 106 No (B16F10) RGD
No No HA
ND No RGD
No No HA
ND No (B16F10) RGD
1 3 107 Yes (B16F10) RGD
6 3 107 ND HA
6 3 107 ND HA
6 3 106 HA
6 3 108 Yes (IB3) HA/SERP
4.6 3 104 Yes/no (KG-1) sFv anti-CD34
No HA
No HA
No No Histidine
6 3 108 Yes (IB3) HA/SERP
No No (A9 HABK2) BRDY
No No (A9 HABK2) BRDY
No No (A9 HABK2) BRDY
are at the amino and carboxy termini of Vp1, 2, and 3. The next 5 were
as described by the authors.
ional epitope.
issive cells.
itope inserts.
I or KFNKPFVFLI), histidine (ASGGHHHHHHHHGGSA), BRDY (brady-ABLE 2
Insert
(6)d
e
e
wn
e
e
e
ve
e
e
e
e
e
e
e
e
sid
sid
ve
e
e
e
e
next 5
ELISA
format
2-perm
with epmining surface localized domains that will display target-
ing ligands (i.e., three positions have been determined by
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307MINIREVIEWthe genetic approach and one by chemical cross-link-
ing). Although limited in number, these mutants illustrate
the point of extending the host range of AAV type 2 by
capsid alteration. A more extensive repertoire of inser-
tion sites that allow for targeting epitopes coupled with
mutants that have lost the ability to bind heparin will
eventually provide the gene therapy field a new genera-
tion of AAV targeting vectors.
CONCLUSIONS
The utility of adeno-associated virus type 2 as a gene
therapy vector is just beginning to be exploited. Produc-
tion and purification protocols have improved the titer
and quality of AAV vectors available for clinical trials
(Monahan and Samulski, 2000). However, preexisting
immunity to natural infections could limit the extended
use of this vector. Therefore, it is clear that alternative
strategies must be investigated to resolve this problem.
At present, the five serotypes of AAV will aid in resolving
vector readministration. Preliminary evidence indicates
that some of these serotypes do not cross-react and
more importantly have different tissue tropism. The se-
rotype-specific tropism provides the unique opportunity
for transducing distinct cell types in vivo more efficiently
Chao et al., 2000). Ultimately, a molecular understanding
f the entry pathways for the various AAV serotypes will
e required to fully exploit this attribute (i.e., identification
f AAV type 2 primary and secondary receptors). This
oupled with the genetic analysis of AAV capsids should
dvance the field in the development of new parvovirus
argeting vectors. At present, it is expected that the
arious serotypes of AAV (i.e., types 1 and 5) will displace
AV type 2 for certain in vivo gene delivery applications.
his is based on preliminary studies that demonstrate
on AAV type 2 vectors are more suited to transduce
ertain target cells in vivo (i.e., brain, lung, muscle, etc.).
However, it is predicted that laboratory generated chi-
meric viruses composed of preferred portions from these
various serotypes (e.g., type 1/2), will eventually displace
all serotype specific vectors for use in human gene
therapy. These custom designed delivery systems will no
doubt prove that building a better vector by manipulating
the AAV virion is a feasible and justified endeavor.
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